drug-eluting stents

¿Es frecuente el uso de IVUS para guiar la ATC?

Optimization by IVUS after FFR Guided PCI: Are There Clinical Benefits for Patients?

Percutaneous coronary interventions have improved during the last decade with 15% rate of target vessel failure (TVF) at 5 years according to the latest reports. We are already familiar with the benefits of functional assessment of lesions with FFR and its clinical outcomes.&nbsp; Additionally, low post PCI FFR values (FFR 0.83-0.91) have been associated<a href="https://solaci.org/en/2022/08/24/optimization-by-ivus-after-ffr-guided-pci-are-there-clinical-benefits-for-patients/" title="Read more" >...</a>

The Best of the SOLACI-SOCIME 2022 Main Arena: Day 3

Lecture by Dr. Hector García García &#8211; LM-PCI: IVUS and FFR/IFR? Dr. Hector García delivered an excellent presentation on whether we should use intravascular ultrasound (IVUS) or fractional flow reserve (FFR)/instantaneous wave-free ratio (iFR) in the left main coronary artery (LMCA) to consider severe obstruction, since there is significant interobserver variability with angiography. Although the<a href="https://solaci.org/en/2022/08/11/the-best-of-the-solaci-socime-2022-main-arena-day-3/" title="Read more" >...</a>

Pacientes que no siguen nuestro consejo y sorpresivamente tienen menos eventos

Angioplasty in Nonagenarians Is Increasingly Frequent: How Does It Evolve?

Currently, the number of nonagenarian patients undergoing angioplasty (whether elective, urgent or emergency) has increased.&nbsp; This population is linked to more comorbidities and has barely been included in most randomized studies or registries. As such, we do not have robust evidence on this group. Researchers conducted an analysis of the J-PCI OUTCOME Registry, in which<a href="https://solaci.org/en/2022/07/19/angioplasty-in-nonagenarians-is-increasingly-frequent-how-does-it-evolve/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel. Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons. The aim of this randomized, multicenter study was to evaluate<a href="https://solaci.org/en/2022/06/13/using-biolimus-coated-balloons-for-treating-small-vessel-disease-yields-promising-results/" title="Read more" >...</a>

IVUS vs OCT para guiar la angioplastia ¿Cuál elegir?

IVUS-Guided Coronary Angioplasty: Promising Results at 3-Year Follow-Up

Intravascular ultrasound (IVUS) to guide drug-eluting stent (DES) implantation has been evaluated in several studies. Two randomized studies, IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) and ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-Comers Coronary Lesions), have shown fewer repeat revascularizations compared with angiography-guided<a href="https://solaci.org/en/2022/05/02/ivus-guided-coronary-angioplasty-promising-results-at-3-year-follow-up/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

REVERSE-IT | Bentracimab: Progress on the Antidote for Ticagrelor in Emergency Scenarios

Optimizing an antiplatelet therapy after an acute coronary syndrome (ACS) aims at reducing the major adverse cardiac events (MACE) caused by atherosclerotic disease. Ticagrelor is a potent P2Y12 inhibitor that directly prevents platelet activation. It is characterized by a rapid and consistent onset of action throughout its administration (twice daily) and its proven pleiotropic effects,<a href="https://solaci.org/en/2022/03/25/reverse-it-bentracimab-progress-on-the-antidote-for-ticagrelor-in-emergency-scenarios/" title="Read more" >...</a>

Escándalo con los resultados del EXCEL que hicieron “caer” las últimas guías

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might limit the applicability of older randomized trials to contemporary clinical practice. In this case, we look at patients and devices used in the contemporary clinical practice vs. those in the EXTEND DAPT. These differences were associated with attenuated<a href="https://solaci.org/en/2022/01/25/clnical-practice-dissociated-from-study-outcomes-bad-news-for-our-patients/" title="Read more" >...</a>

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last years works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>

The Most Read Articles of 2021: Pharmacology

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, pharmacology. Follow us to keep up to date. The Most Read Articles of 2021: Pharmacology 01- Swan Ganz Associated with Better Outcomes in Cardiogenic Shock: Is It Back? The&nbsp;Swan<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-pharmacology/" title="Read more" >...</a>

The Most Read Articles of 2021: Coronary Disease

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. Most Read Articles on Coronary Disease 01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-coronary-disease/" title="Read more" >...</a>

Top